Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

BACKGROUND AND OBJECTIVE: Nonacog beta pegol (N9‐GP) and recombinant factor IX‐Fc fusion protein (rFIXFc) are extended half‐life rFIX compounds. We report the first single‐dose pharmacokinetic trial of N9‐GP and rFIXFc. PATIENTS/METHODS: Paradigm 7 was a multicenter, open‐label, randomized, crossove...

Full description

Saved in:
Bibliographic Details
Published in:Res Pract Thromb Haemost
Main Authors: Escuriola Ettingshausen, Carmen, Hegemann, Inga, Simpson, Mindy L., Cuker, Adam, Kulkarni, Roshni, Pruthi, Rajiv K., Garly, May‐Lill, Meldgaard, Rikke M., Persson, Paula, Klamroth, Robert
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Original Articles: Haemostasis
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6462750/
https://ncbi.nlm.nih.gov/pubmed/31011711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12192
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items